

IN THE CLAIMS:

The status of each claim that has been introduced in the above-referenced application is identified in the ensuing listing of the claims. This listing of the claims replaces all previously submitted claims listings.

1. (Currently amended) A method for causing a treated animal to elicit a T-cell mediated immune response, comprising administering to the treated animal a quantity of a composition including an extract of an egg obtained from a source animal, ~~said-the~~ extract comprising consisting essentially of water soluble proteins of a yolk of an egg having molecular weights of about 8,000 Da or less, including transfer factor, generated by said-the source animal in a T-cell mediated immune response to at least one antigenic agent, ~~treated to purify said transfer factor from other proteins or peptides of the at least one egg having molecular weights of greater than about 8,000 Da,~~ and present in a concentration greater than that present in the egg and in a sufficient quantity to initiate ~~said-the~~ T-cell mediated immune response in the treated animal.

2. (Currently amended) The method of claim 1, wherein ~~said-administering~~ comprises administering to the treated animal a quantity of ~~said-the~~ composition with said-the extract comprising transfer factor molecules having molecular weights of about 4,000 Da to about 5,000 Da.

3. (Currently amended) The method of claim 1, wherein ~~said-administering~~ is effected orally.

4. (Currently amended) The method of claim 1, wherein ~~said-administering~~ is effected nasally.

5. (Currently amended) The method of claim 1, wherein ~~said-administering~~ is effected parenterally.

6. (Currently amended) The method of claim 1, wherein ~~said~~-administering is effected topically.

7. (Currently amended) The method of claim 1, wherein ~~said~~-administering comprises administering a sufficient quantity of ~~said-the~~ composition to cause an immune system of the treated animal to elicit an immune response against an infection by a pathogen associated with ~~said-the~~ antigenic agent.

8. (Currently amended) The method of claim 7, wherein ~~said~~-administering is effected before the treated animal is exposed to ~~said-the~~ pathogen.

9. (Currently amended) The method of claim 7, wherein ~~said~~-administering is effected after the treated animal has been exposed to ~~said-the~~ pathogen.

10. (Currently amended) The method of claim 7, wherein ~~said~~-administering also comprises administering to the treated animal ~~said-the~~ composition with ~~said-the~~ transfer factor comprising transfer factor molecules specific for at least one antigen of ~~said-the~~ pathogen.

11. (Currently amended) The method of claim 1, wherein ~~said~~-administering comprises administering a sufficient quantity of ~~said-the~~ composition to treat a symptom associated with infection by a pathogen associated with ~~said-the~~ antigenic agent.

12. (Currently amended) The method of claim 11, wherein ~~said~~-administering also comprises administering to the treated animal ~~said-the~~ composition with ~~said-the~~ transfer factor comprising transfer factor molecules specific for at least one antigen of ~~said-the~~ pathogen.

13. (Currently amended) The method of claim 1, wherein ~~said~~-administering comprises administering to the treated animal ~~said-the~~ composition with ~~said-the~~ transfer factor comprising transfer factor molecules specific for at least one antigen of at least one antigenic agent.

14. (Currently amended) The method of claim 1, wherein ~~said~~-administering comprises administering to the treated animal ~~said-the~~ composition with ~~said-the~~ transfer factor comprising transfer factor molecules specific for at least one antigen of at least one of Newcastle Virus, rubeola virus, mumps virus, rubella virus, Epstein-Barr Virus, hepatitis B virus, and *H. pylori*.

15. (Currently amended) The method of claim 1, wherein ~~said~~-administering comprises administering ~~said-the~~ composition to a mammal.

16. (Currently amended) The method of claim 1, wherein ~~said~~-administering comprises administering to the treated animal ~~said-the~~ composition with ~~said-the~~ egg extract comprising an extract of an avian egg.

17. (Canceled)

18. (Currently amended) The method of claim 1, wherein ~~said~~-administering comprises administering to the treated animal ~~said-the~~ composition with ~~said-the~~ egg extract comprising non-mammalian transfer factor.

19. (Currently amended) The method of claim 1, wherein, following ~~said~~ administering, ~~said-the~~ transfer factor causes the treated animal, *in vivo*, to elicit the T-cell mediated immune response.

20. (Currently amended) A method for causing an animal to elicit a T-cell mediated immune response, comprising:
administering to the treated animal a quantity of a composition including an extract of an egg obtained from a source animal and consisting essentially of water soluble proteins of a yolk of treated to purify said transfer factor from other proteins or peptides of the at least one egg, including transfer factor, that have having molecular weights of greater than about 8,000 Da or less, the said extract comprising a sufficient quantity of the transfer factor, generated by said the source animal in a T-cell mediated immune response to at least one antigenic agent, to initiate said the T-cell mediated immune response in the treated animal; and
permitting the transfer factor and the animal's immune system to initiate the T-cell mediated immune response *in vivo*.

21. (Currently amended) The method of claim 20, wherein ~~said~~ administering comprises administering to the treated animal a quantity of ~~said the~~ composition with ~~said the~~ extract comprising transfer factor molecules having molecular weights of about 4,000 Da to about 5,000 Da.

22. (Currently amended) The method of claim 1, wherein ~~said the~~ administering comprises administering to the treated animal a sufficient quantity of ~~said the~~ composition to enhance an ability of the immune system of the treated animal to elicit an increased T-cell mediated immune response relative the treated animal's normal T-cell mediated immune response to the at least one antigenic agent.

23. (Currently amended) The method of claim 1, wherein ~~said~~-administering comprises administering to the treated animal ~~said the~~ composition with ~~said the~~ egg extract comprising an extract of a non-avian egg.

24. (Canceled)

25. (Canceled)